Metabolic syndrome and prostate cancer: a review.
Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.
Nobes
J P
JP
St. Luke's Cancer Centre, The Royal Surrey County Hospital, Guildford, Surrey, UK. jpnobes@gmail.com
Langley
S E M
SE
Laing
R W
RW
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology*; D009919:Orchiectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone